Sutent price (correction)
Executive Summary
Based on the wholesale acquisition cost of Sutent (sunitinib), which is $6,412.50 for a 30 count bottle of 50 mg capsules, the product's average monthly cost is $4,275. This prices Sutent at a slight discount to Bayer/Onyx' Nexavar (sorafenib) which carries a WAC of $4,333 for a one-month supply. In a previous story on the approval of Sutent, "The Pink Sheet" incorrectly identified the price of the product and incorrectly referred to the average wholesale price of Nexavar as the price to patients (1"The Pink Sheet" Jan. 30, 2006, p. 4)...
You may also be interested in...
Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar
Pfizer's newly approved oncologic Sutent will have a dosing advantage and will be priced at a slight discount compared to Bayer/Onyx' Nexavar
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.